Evidence map›Paper›PMID 30810053›Full record

ArticleExpert opinion on therapeutic targets2019

The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease.

Emily K Cook, Gabrielle L Sell, Thomas B Schaffer, Seth S Margolis

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on therapeutic targets, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Emily K Cooka Department of Biological Chemistry , The Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Gabrielle L Sellb Center for Neuroscience , University of California , Davis , CA , USA.
Thomas B Schafferc Research and Development , Columbia Biosciences Corporation , Frederick , MD , USA.
Seth S Margolisa Department of Biological Chemistry , The Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Johns Hopkins Medicine · USUniversity of California, Davis · US

Funding

BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Neuroscience Training ProgramT32EY017203 · NEI · JOHNS HOPKINS UNIVERSITY · PI BERGLES, DWIGHT E · 2005 to 2014
$2.9M
Molecular Mechanisms of UBE3A Mediated Synapse Development in Angelman SyndromeR01MH102364 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MARGOLIS, SETH S · 2014 to 2018
$2.0M
NEI NIH HHS T32 EY017203NIGMS NIH HHS T32 GM007445NIMH NIH HHS R01 MH102364
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyAgedAlzheimer DiseaseAnimalsGuanine Nucleotide Exchange FactorsHumansARHGEF15 protein, humanGuanine Nucleotide Exchange Factors

Identifiers

PMID30810053
PMCPMC6715421
OpenAlexW2917865535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.